

Johannes Leierer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6168770/publications.pdf>

Version: 2024-02-01

15
papers

645
citations

840776

11
h-index

1058476

14
g-index

15
all docs

15
docs citations

15
times ranked

1199
citing authors

#	ARTICLE	IF	CITATIONS
1	Empagliflozin Inhibits IL-1 β -Mediated Inflammatory Response in Human Proximal Tubular Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5089.	4.1	15
2	Coregulation Analysis of Mechanistic Biomarkers in Autosomal Dominant Polycystic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6885.	4.1	6
3	Empagliflozin Inhibits Basal and IL-1 β -Mediated MCP-1/CCL2 and Endothelin-1 Expression in Human Proximal Tubular Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8189.	4.1	19
4	Computational Drug Screening Identifies Compounds Targeting Renal Age-associated Molecular Profiles. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 843-853.	4.1	6
5	Considerable international variation exists in blood pressure control and antihypertensive prescription patterns in chronic kidney disease. <i>Kidney International</i> , 2019, 96, 983-994.	5.2	51
6	Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. <i>Diabetologia</i> , 2019, 62, 1154-1166.	6.3	284
7	Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, F449-F462.	2.7	37
8	Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 47-56.	2.0	17
9	Identification of dicarbonyl and L-xylulose reductase as a therapeutic target in human chronic kidney disease. <i>JCI Insight</i> , 2019, 4, .	5.0	5
10	A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) – Study Design and Baseline Characteristics. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 181-190.	2.0	27
11	Effect of cyclosporine, tacrolimus and sirolimus on cellular senescence in renal epithelial cells. <i>Toxicology in Vitro</i> , 2018, 48, 86-92.	2.4	17
12	Systems Medicine Derived Biomarkers to Assess How Canagliflozin Delays Progression of Diabetic Kidney Disease. <i>Diabetes</i> , 2018, 67, 1126-P.	0.6	0
13	Urinary peptidomics analysis reveals proteases involved in diabetic nephropathy. <i>Scientific Reports</i> , 2017, 7, 15160.	3.3	28
14	Renal microRNA and miRNA profiles in progressive chronic kidney disease. <i>European Journal of Clinical Investigation</i> , 2016, 46, 213-226.	3.4	96
15	Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 930-936.	0.7	37